Privium Fund Management B.V. Has $597,000 Stake in Rocket Pharmaceuticals, Inc. $RCKT

Privium Fund Management B.V. decreased its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 60.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 170,146 shares of the biotechnology company’s stock after selling 262,614 shares during the period. Privium Fund Management B.V.’s holdings in Rocket Pharmaceuticals were worth $597,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC boosted its stake in Rocket Pharmaceuticals by 63.5% in the 4th quarter. Sanctuary Advisors LLC now owns 17,437 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 6,769 shares during the period. Evergreen Capital Management LLC acquired a new position in Rocket Pharmaceuticals in the 4th quarter worth approximately $45,000. Hennion & Walsh Asset Management Inc. boosted its stake in Rocket Pharmaceuticals by 1.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 309,247 shares of the biotechnology company’s stock worth $1,085,000 after purchasing an additional 3,809 shares during the period. SG Americas Securities LLC boosted its stake in shares of Rocket Pharmaceuticals by 30.8% during the 4th quarter. SG Americas Securities LLC now owns 63,748 shares of the biotechnology company’s stock valued at $224,000 after buying an additional 15,019 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Rocket Pharmaceuticals by 73.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,097,033 shares of the biotechnology company’s stock valued at $6,836,000 after buying an additional 889,231 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Insider Buying and Selling at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah sold 12,279 shares of the business’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,643.49. Following the transaction, the chief executive officer owned 1,052,045 shares in the company, valued at approximately $3,482,268.95. The trade was a 1.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Martin Wilson sold 12,253 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,557.43. Following the transaction, the general counsel owned 683,376 shares in the company, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 29,415 shares of company stock worth $97,398 in the last quarter. Insiders own 21.30% of the company’s stock.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT opened at $3.54 on Wednesday. The company has a market capitalization of $386.28 million, a PE ratio of -1.76 and a beta of 0.52. Rocket Pharmaceuticals, Inc. has a one year low of $2.19 and a one year high of $7.77. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.38 and a quick ratio of 6.38. The company’s fifty day moving average price is $4.11 and its 200 day moving average price is $3.69.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. During the same quarter in the prior year, the company posted ($0.62) earnings per share. As a group, analysts expect that Rocket Pharmaceuticals, Inc. will post -1.68 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RCKT. The Goldman Sachs Group lifted their target price on shares of Rocket Pharmaceuticals to $3.00 and gave the company a “sell” rating in a research note on Monday, March 2nd. Weiss Ratings raised shares of Rocket Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Chardan Capital reissued a “buy” rating and set a $11.00 target price on shares of Rocket Pharmaceuticals in a research note on Friday, March 27th. Bank of America lifted their target price on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Finally, Lifesci Capital raised shares of Rocket Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.86.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.